A global pharmaceutical company successfully built a unified corporate reputation across 50+ emerging markets by implementing a strategic corporate affairs blueprint. By combining a central expert team in its Singapore HQ with on-the-ground local support, the company enhanced stakeholder relations and transformed its crisis managementframework. This agile approach enabled the business to navigate corporate restructurings and successfully launch a flagship Dengue vaccine in key Latin America and APAC markets.

A Growth & Emerging Markets business unit, from a global pharmaceutical company, which oversees more than 50 countries, faced challenges related to low corporate brand awareness and limited in-house team capacity. The objective was to upgrade its corporate reputation and stakeholder relations across these highly diverse markets. This included defining the GEM unit's role, auditing reputational risks, and equipping local teams for effective delivery.

A senior team of global and regional experts from Speyside Group worked directly alongside the company in its Singapore HQ. This central team was supported by local teams on the ground in key markets who were responsible for feeding local news and insights, advising the localization of plans, and partnering with the client's local teams on execution.

The company's approach to issues and crisis management was transformed and successfully stress-tested during the COVID-19 pandemic. The support helped the business navigate key milestones, including multiple corporate restructurings, the launch of a flagship Dengue vaccine in Latin America and APAC, and the rollout of global access to medicines and patient engagement programs.